Who's Watching The Watchmen This Time? The Mystery Of The New IRB Sting
This article was originally published in The Pink Sheet Daily
Executive Summary
Institutional review boards appear to be facing vigilante regulation as FDA warns that someone is submitting fictitious studies for review.